Abstract
Results
Among the 504 studies screened, 45 studies with a total of 36,588 participants were included in this review. The pooled prevalence of type II endoleaks after EVAR was 22% [95% confidence interval (CI), 19%-25%]. The main factors consistently associated with type II endoleaks included age [pooled odds ratio (OR), 0.37; 95% CI, 0.31-0.43; P<0.001], smoking (pooled OR, 0.71; 95% CI, 0.55-0.92; P<0.001), patent inferior mesenteric artery (pooled OR, 1.98; 95% CI, 1.06-3.71; P = 0.012), maximum aneurysm diameter (pooled OR, 0.23; 95% CI, 0.17-0.30; P<0.001), and number of patent lumbar arteries (pooled OR, 3.07; 95% CI, 2.81-3.33; P<0.001). Sex, diabetes, hypertension, anticoagulants, antiplatelet, hyperlipidemia, chronic renal insufficiency, types of graft material, and chronic obstructive pulmonary diseases (COPD) did not show any association with the onset of type II endoleaks.
Conclusions
Clinicians can use the identified risk factors to detect and manage patients at risk of developing type II endoleaks after EVAR. However, further studies are needed to analyze a number of potential risk factors. a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
Introduction
Endovascular aneurysm repair (EVAR) has become the primary choice of treatment for abdominal aortic aneurysms (AAAs) in suitable patients [1] . EVAR always has better shortterm outcomes compared with open repair [2, 3] . Aortic endograft occlusion, migration, and endoleaks are known complications after EVAR [4] , among which endoleaks are the most frequent. Types I and III endoleaks require urgent intervention to relieve aneurysm re-pressurization [5, 6] . Type II endoleaks are caused by backflow of collateral arteries into the aneurysm sac, with an occurrence rate of 10.2% after EVAR [7] . Type II endoleaks do not exert any immediate adverse effects. However, persistent type II endoleaks are believed to be associated with increased sac pressure and cause adverse outcomes and even aneurysm rupture [8] .
Various studies assessed risk factors for type II endoleaks following EVAR [9] [10] [11] . Potential correlations may exist between preoperative characteristics and development of type II endoleaks [9] . A patent inferior mesenteric artery (IMA) and the number of patent lumbar arteries have been investigated as risk factors for type II endoleaks [10, 11] . However, no previous systematic review has concentrated on this topic. Hence, the primary objective of the present systematic review and meta-analysis was to determine the current evidence on risk factors for the onset of type II endoleaks. This review concentrated on nonclinical risk factors, such as sex and age, preoperative comorbidities, and aortic anatomy. Moreover, we intended to report the updated pooled prevalence of type II endoleaks after EVAR.
Methods

Search strategy and study selection
Relevant publications were identified by searching the following database: MEDLINE (from Jan 1, 1950, to June 30, 2016) (S1 File), Scopus (from 1966 to June 30, 2016), and EMBASE (from 1966 to June 30, 2016). The terms "type II endoleak" or "type 2 endoleak," "endovascular," and "aneurysm" were searched. The references cited in published original and review articles were searched to identify additional studies. The search was limited to human adults and publications in English. Subsequently, two authors (Q.G. and X.D.) independently reviewed the title and abstract of the studies identified in the search to exclude those that did not answer the research question of interest in accordance with prespecified inclusion and exclusion criteria. Records extracted by the initial search were screened, and potentially relevant papers were retrieved and examined in detail. Duplicate publications and case reports were also excluded. Whenever publications of overlapping populations were available, the publication with the most complete and relevant set of data was chosen.
We identified studies in accordance with the following inclusion criteria: (1) participants: human adults (minimum of 18 years of age) with abdominal aortic aneurysm; (2) intervention: EVAR; (3) comparison: patients with potential risk factors versus patients without potential risk factors resulting in type II endoleaks; and (4) sufficient data were available for estimating an odds ratio (OR) with confidence interval (CI).
diameter, and number of patent lumbar arteries]. Conflicts in data abstraction were resolved through consensus by referring back to the original article. The methodological quality of the studies was assessed by two authors (D.Y. and Y.Y.) independently using the NewcastleOttawa scale [12] . Quality was calculated on the basis of the following three aspects of study design: patient selection, comparability of study groups, and exposure and outcome of study participants. Studies that scored 5 or greater were considered high quality, whereas those that scored 4 and below were considered low quality.
Statistical analysis
Statistical analyses were performed with Stata 12.0 software (StataCorp LP, College Station, Texas, USA). Dichotomous variables were analyzed by estimating the odds ratio (OR) with a 95% confidence interval (95% CI), whereas continuous variables were analyzed using the weighted mean difference with a 95% CI. Statistical heterogeneity between studies was assessed using the I 2 measure. I 2 > 50% was considered to indicate high statistical heterogeneity. If no heterogeneity was found, a fixed effect model based on the Mantel and Haenszel estimator was used; otherwise, a random effect model based on the DerSimonian and Laird estimator was used [13] . 
Results
Study characteristics and methodological quality
From the 504 studies identified using our search strategy, 73 potentially relevant articles were retrieved and assessed for eligibility. In total, 45 papers were included in this review [8] [9] [10] [11] , with 15 included in the meta-analysis [8, 9, 28, [32] [33] [34] 37, 38, [45] [46] [47] [48] 50, 55, 56] . The flow diagram summarizing the study identification and selection is shown in Fig 1. The characteristics of the included studies are reported in Table 1 . The methodological quality of the included studies for meta-analysis is summarized in S3 File. All of the studies enrolled for meta-analysis were of high quality. 
Prevalence of type II endoleaks after EVAR
Meta-analysis of possible factors associated with type II endoleak
In total, eight studies reported on the effect of age on type II endoleaks (Table 3 ). These studies consistently demonstrated that age was a risk factor for the onset of type II endoleaks, although considerable heterogeneity was present among the results reported (I 2 = 99.0%). The pooled OR of the eight studies was 0.37 (95% CI, 0.31-0.43; P<0.001). Twelve studies investigated smoking as a risk factor for the onset of type II endoleaks. Among these 14 studies, a considerable heterogeneity was observed between the study findings (I 2 = 86.4%); however, all studies were generally consistent in reporting smoking as a protective factor for the onset of type II endoleaks. The pooled OR of the 12 studies was 0.71 (95% CI, 0.55-0.92; P<0.001). Seven cohort studies assessed the effect of maximum aneurysm diameter on the onset of type II endoleaks. The I 2 among the seven studies was 98.0%, and the resulting pooled OR was 0.23 (CI, 0.17-0.30; P = 0.012), showing an increased risk of type II endoleaks in patients with a greater diameter of AAA. Three studies were included in the meta-analysis of patent IMA as a risk factor for the onset of type II endoleaks. The extent of heterogeneity present between the (Table 3) .
Sensitivity analyses by quality (methodological quality >6), and sample size (n>100) were done for the enrolled studies. All meta-analytic conclusions remained robust to this testing. The results of Begg's test (p = 0.432) and Egger's test (p = 0.338) revealed no significant publication bias in this study.
Discussion
Endoleaks are specific complications of EVAR. Type II endoleaks are the most common type of endoleaks, occurring in approximately 10% of patients after EVAR [7] . Although Type II endoleaks are less likely to require secondary reintervention than type I or III endoleaks because of the possibility of arterial rupture [9] , type II endoleaks are a risk factor for aneurysm sac growth, and ruptures occur in approximately 1% of patients with type II endoleaks after EVAR [7] . Thus, patients need continuous surveillance after EVAR to detect aneurysm growth and endoleaks. Previous studies explored risk factors for type II endoleaks after EVAR [9] [10] [11] . However, controversies have been found between these studies. These discrepancies may be attributed to the insufficient statistical power of individual studies and the inability to perform separate analyses. Therefore, we conducted a systematic review and meta-analysis to identify the risk factors for type II endoleaks after EVAR. Furthermore, the pooled prevalence of type II endoleaks must be updated on the basis of the latest evidence.
Among the potential risk factors for type II endoleaks, older age, patent inferior mesenteric artery, number of patent lumbar arteries, and maximum aneurysm diameter significantly increase the risk for type II endoleaks after EVAR. By contrast, smoking is a protective factor for type II endoleaks. Sex, diabetes, hypertension, anticoagulants, hyperlipidemia, chronic renal insufficiency, COPD, and polytrafluoroethylene-based endografts are not associated with the onset of type II endoleaks. To the best of our knowledge, this systematic review and meta-analysis is the first to identify the risk factors of type II endoleaks after EVAR. This paper also revealed a higher prevalence of type II endoleaks after EVAR compared with an earlier review [7] . Most of the included studies exhibited high methodological quality on the basis of the Newcastle-Ottawa scale. Statistical tests were performed to examine the issue of publication bias, and results revealed no statistically significant publication bias. [44] . Moreover, the endovascular reinterventions for type II endoleaks associated with an enlargement of the aneurysmal sac after EVAR have a poor effectiveness on the stabilization of the diameter of the AAA [36] . Other studies stated that recurrent and persistent type II endoleaks are prone to life-threatening complications, and type II endoleak appears to be a marker of EVAR failure that is difficult to predict and treat effectively [34, 37] . The debate about the indication of intervention for type II endoleaks seems to last.
From the anatomic aspect, we identified patent IMA, number of patent lumbar arteries, and maximum aneurysm diameter as risk factors for the onset of type II endoleaks. Preoperative embolization of the IMA has been proved to be associated with decreased risk of type-2 endoleak and aneurysm sac enlargement after EVAR [57] . Considering aneurysm diameter, it is likely that the increased flow channel within the aneurysm sac coupled with a larger number of patent aortic branch vessels leads to increased flow velocities within the sac, thus decreasing the likelihood of type II endoleak resolution [58] . It is reported that the number of patent lumbar arteries was also correlated with onset of type II endoleak, however, this study did not include the analysis because no other studies reported the similar issue [9] . In total, 12 studies investigated smoking as a risk factor for the onset of type II endoleaks. All studies were generally consistent in reporting smoking as a protective factor for the onset of type II endoleaks. Koole et al.
[32] reported a study that analyzed the data of 8638 patients who were enrolled prospectively in the European Collaborators on Stent-Graft Techniques for Aortic Aneurysm Repair database. The study observed decreased intraoperative perfusion from the mesenteric inferior artery or lumbar arteries in smokers. The explanation of these findings remains unclear; however, we hypothesized that tobacco use can induce the atherosclerotic injury of medium-and small-sized vessels, which may narrow or occlude these arteries and thereby impair the blood flow [32] . There is also an increased tendency of coagulation in smokers, which also might narrow or occlude the arteries. We also found that older age is a risk factor for the onset of type II endoleaks. Long history and large diameter of AAA in aging patients, favoring high-pressure aneurysm sac, may be a possible explanation of this fact. Besides, aging patients might also have more severe atherosclerotic injury of vessels which induced impair of the retrograde flow into abdominal aorta.
Our review also has some limitations. First, only the main predictors drawn from the articles were analyzed because of data deficiencies. Second, our study was subjected to heterogeneity in some of the inclusion criteria, as well as relatively small sample sizes and numbers of articles, which may have caused potential publication bias. Only three studies were included in the metaanalysis of patent IMA as a risk factor for the onset of type II endoleaks, whereas only four studies provided data that compared the effects of anticoagulants used on the onset of type II endoleaks. Furthermore, most of the articles included in our review are retrospective observational studies. A long-term prospective study to specifically define risk factors of endoleaks would be instructive.
In conclusion, age, patent inferior mesenteric artery, number of patent lumbar arteries, maximum aneurysm diameter, and non-tobacco use are significant factors in predicting type II endoleaks. Meanwhile, sex, diabetes, hypertension, anticoagulants, antiplatelet, hyperlipidemia, chronic renal insufficiency, types of graft material, and COPD show no statistical significance. Thus, clinicians should pay attention to these factors in AAA patients after EVAR. 
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